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Manuscript received May 17, 2016 and accepted July 18, 2016AbstractThe prodrug droxidopa increases blood pressure (BP) in patients with neurogenic orthostatic hypotension. The BP profile of
droxidopa in neurogenic orthostatic hypotension patients (n ¼ 18) was investigated using ambulatory BP monitoring.
Following dose optimization and a washout period, 24-hour ‘‘off-drug’’ data were collected. ‘‘On-drug’’ assessment was con-
ducted after 4–5 weeks of droxidopa treatment (mean dose, 444 mg, three times daily). Ambulatory monitoring off drug re-
vealed that 90% of patients already had abnormalities in the circadian BP profile and did not meet criteria for normal nocturnal
BP dipping. On treatment, both overall mean 24-hour systolic and diastolic BPs were higher compared to off drug (137/81 mm
Hg vs. 129/76 mm Hg; P ¼ .017/.002). Mean daytime systolic BP was significantly higher with droxidopa (8.4  3.1 mm Hg;
P ¼ .014). Although nocturnal BP was not significantly higher on droxidopa versus off treatment (P ¼ .122), increases in
nocturnal (supine) BP 10 mm Hg were observed in four cases (22%). Severe supine systolic hypertensive readings at night
(>200 mmHg) were captured in one case and only while on treatment. These data demonstrate that ambulatory BP monitoring
is useful to evaluate the circadian BP profile after initiating treatment with a pressor agent. J Am Soc Hypertens
2016;10(10):819–826.  2016 The Authors. Published by Elsevier Inc. on behalf of American Society of Hypertension.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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perfusion, with cardinal symptoms including disabling
lightheadedness or syncope.7
Droxidopa (L-threo-3,4-dihydroxyphenylserine) is a syn-
thetic amino acid that is converted to norepinephrine by the
ubiquitous enzyme, dopa-decarboxylase.1,8 Clinical trials
show that oral administration of droxidopa produces a pres-
sor response that lasts for approximately 6 hours.8,9 The BP
response is associated with an improvement in symptoms of
nOH in patients with synucleinopathies and chronic auto-
nomic failure.10–12 Droxidopa is approved in the United
States for the treatment of patients with symptomatic nOH.
During clinical trials, the impact of droxidopa on BP was
assessed using BP measurements acquired during an office
visit. However, in patients with nOH, office BP readings do
not fully characterize the circadian variation of BP.13 In clin-
ical practice, ambulatory BP monitoring is often used to eval-
uate the response to treatment with pressor agents throughout
a typical day.13 In addition to capturing BP variations while
awake, it can also be used to assess nocturnal BP, which is
often elevated in patients with synucleinopathies and auto-
nomic failure. Supine hypertension is often worsened by the
very therapies used to treat daytime orthostatic hypoten-
sion,14,15 which creates a difficult clinical conundrum.
Here, we examined the ambulatory BP profiles in pa-
tients with symptomatic nOH associated with synucleino-
pathies on droxidopa and compared these values to those
following a washout period off drug.MethodsStudy DesignThe ambulatory BP study was conducted as a component
of a multicenter, randomized trial of droxidopa and open-
label extension studies in individuals with nOH as a result
of autonomic failure.11,16,17 The protocol was approved by
the site-specific institutional review boards, and written
informed consent was obtained for all participants.Parent Randomized 
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Figure 1. Design of the 24-hour ambulaProcedures were performed in accordance with the standards
of the Declaration of Helsinki. All data were deidentified.
Subjects were recruited for this substudy from those
individuals participating in a randomized controlled trial of
droxidopa11 and who were intending to participate in the
open-label extension trials.16,17 Subjects were screened for
eligibility, and suitable candidates were enrolled in an open-
label dose optimization titration phase of the randomized
double-blind, placebo-controlled 1-week clinical trial
(Figure 1). Following the dose optimization phase, subjects un-
derwent awashout period for aminimumof 2 days, and then, an
ambulatory BP recording was obtained (off-drug reading).
Upon completion of the randomized clinical trial, participants
resumed their optimal droxidopa dose in the open-label exten-
sion studies. After a minimum of 4 weeks of open-label treat-
ment, an ambulatory BP recording was obtained.Inclusion and Exclusion CriteriaTo be eligible for inclusion in the study, patients had to be
older than 18 years and have a clinical diagnosis of nOH due
to Parkinson disease, pure autonomic failure, multiple sys-
tem atrophy, or autonomic neuropathy. nOH was defined
as a documented decrease of 20 mm Hg systolic BP or
10 mm Hg diastolic BP within 3 minutes of standing.
Key exclusion criteria included nOH as a result of diabetes,
use of pressor agents such as midodrine, sustained severe hy-
pertension (180/110 mm Hg while seated), and clinically
significant renal, hepatic, or cardiac disease.Droxidopa AdministrationIn the parent randomized controlled trial, dosing of drox-
idopa was initiated at 100 mg three times daily (TID) and
was adjusted upward at subsequent visits until the partici-
pant met any one of the following stopping criteria: (1)
complete resolution of symptoms, (2) reached the
maximum dose of 600 mg TID, (3) development of sus-
tained hypertension (180/110 mm Hg in any position),Open-Label 
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Table 1
Characteristics of the patients at baseline
Patient Age, y Sex Underlying
Diagnosis
Supine
SBP/DBP,
mm Hg
Standing*
SBP/DBP,
mm Hg
Supine
Heart
Rate,
bpm
Standing*
Heart
Rate,
bpm
1 76 M PAF 130/78 78/30 109 NA
2 66 M PAF 174/92 113/83 74 74
3 75 M PD 111/62 98/59 79 81
4 78 M PD 128/72 98/55 90 70
5 72 F PD 124/72 114/60 80 80
6 75 M PD 110/78 78/50 76 92
7 79 M MSA 120/68 68/40 66 60
8 75 F PD 130/60 90/60 84 84
9 78 M PAF 128/74 68/50 66 74
10 62 F MSA 124/88 110/80 84 96
11 80 M PD 139/80 85/55 68 73
12 76 F PD 154/88 51/35 83 87
13 71 F PD 128/81 90/74 76 84
14 75 M PD 135/88 118/77 77 83
15 74 M PAF 149/97 77/59 74 74
16 80 M PD 127/69 81/63 67 82
17 86 M PD 113/68 82/60 80 89
18 61 M PD 118/75 83/55 84 100
Mean  SEM 74  6y NA NA 130  4/77  2 88  4/58  3 79  2 81  2z
bpm, beats per minute; F, female; M, male; MSA, multiple system atrophy; NA, not applicable or missing; PAF, pure autonomic failure;
PD, Parkinson disease; SD, standard deviation; SEM, standard error of the mean.
*After 3 minutes.
yError value reported as SD.
z n ¼ 17.
Table 2
Mean  SEM ambulatory blood pressures and heart rates off and
on treatment with droxidopa in patients with neurogenic ortho-
static hypotension (n ¼ 18)
Variable No
Treatment
Droxidopa Change From off
Treatment to
On Treatment
Ambulatory systolic BP, mm Hg
24 hour 129  3 137  3 7.3  2.8*
Daytimey 123  2 131  3 8.4  3.1*
Nighttimez 136  5 143  6 7.8  4.8
Ambulatory diastolic BP, mm Hg
24 hour 76  2 81  2 4.8  1.3x
Daytimey 74  2 79  2 5.5  1.8*
Nighttimez 78  4 83  3 4.8  2.5
Ambulatory heart rate, beats/min
24-hour 74  1 76  1 þ2.0  0.8
Daytimea 77  2 79  1 þ2.1  1.4
Nighttimez 71  2 72  2 þ0.5  0.9
BP, blood pressure; SEM, standard error of the mean.
*P < .05.
y 8 AM–4 PM.
z 11 PM–5 AM.
xP < .01 vs. off treatment; Wilcoxon signed-rank test.
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as the dose at which criteria 1 or 2 were achieved or the
dose level below which criteria 3 or 4 were met. Following
identification of the optimal dose, patients underwent a
washout period (a minimum of 2 days to a maximum of
5 days); 24-hour ‘‘off-drug’’ data were collected following
the washout period. The minimum 2-day washout was
determined from the known 2- to 3-hour plasma half-life
of droxidopa.9 Patients were then treated with their optimal
dose of droxidopa for 4 to 5 weeks, and an ‘‘on-drug’’
ambulatory assessment was conducted at the end of this
period. Droxidopa was administered in oral doses TID,
which were divided into three equal doses every 4 hours
during the daytime. To avoid worsening of supine hyperten-
sion at night, patients were verbally instructed to take their
last dose of droxidopa no later than 4 hours before going to
bed. Patients were told to sleep with the head of the bed
elevated at a 30-degree angle.BP MonitoringAmbulatory BP was recorded using a validated monitor
(Model 90,207; SpaceLabs Medical, Inc; Issaquah WA,
USA), which was programmed to measure BP at 30-
minute intervals over a 24-hour period. The appropriate
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Figure 2. Changes in ambulatory SBP values from baseline to after 4 weeks of treatment with droxidopa. Connected lines represent
individual patient data points, and bars show group averages (reported as mean  SEM). aFor comparison of baseline versus droxidopa
using paired t test. SBP, systolic blood pressure; SEM, standard error of the mean.
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were fitted to the nondominant arm, as described previ-
ously.18 Quality criteria for an acceptable ambulatory BP
recording included a minimum of 80% valid readings ob-
tained within 24 hours after monitor hookup, and no
more than 2 consecutive hours or 5 nonconsecutive hours
without a valid reading. Quality of the recordings was re-
viewed, and if these criteria were not met, ambulatory re-
cordings were repeated one more time. If quality criteria
were not met after repeating the recording, data were
deemed unsatisfactory and excluded from the analysis.
Blinded ambulatory BP data were transmitted to and re-
viewed by a single source (Integrium Cardiovascular Core
Laboratory, Tustin, CA).AnalysesThe primary objective of the study was to compare mean
24-hour systolic BP at baseline (following drug washout)
with measurements taken after 4 weeks of droxidopa treat-
ment. Secondary end points included the changes in mean
systolic BP during the daytime (defined as 8 AM–4 PM,
when patients were assumed to be awake and physically
active) and nighttime (defined as 11 PM–5 AM, when patients
would be most likely to be in bed and in the supine position).
Variables examined included the presence of nocturnal dip-
ping (defined as a 10% or greater reduction in systolic BP dur-
ing the night compared with the day)19,20 and the incidence of
varying levels of stage 2 hypertension, defined as systolic BP
values of 160, 180, and 200 mm Hg. No efficacy eval-
uations were included in this substudy, and all other safety
variables (beyond BP effects) are reported as part of theparent study (randomized controlled trial11 or open-label
extension trials).16,17Statistical AnalysesComparisons between baseline values and values after
droxidopa treatment were examined using the Wilcoxon
signed-rank test and 95% confidence intervals (CIs)
based on paired t tests. The incidence of hypertension
was determined by the proportions of patients at baseline
and on treatment with various BP values at night
assessed using chi-square and Fisher exact tests. The
incidence of hypotension was determined by the
proportion of patients with daytime systolic BP
readings 80 and 70 mm Hg. Statistical significance
was set at P < .05.
ResultsPatientsA total of 20 patients participated in the ambulatory BP
substudy at eight sites. Two patients were excluded from
the analysis because their ambulatory recordings did not
meet quality criteria. Hence, complete data at baseline
and on treatment were available for 18 patients. The base-
line characteristics of the participants are shown in Table 1.
The mean  standard deviation age of the cohort was
74  6 years, the majority of patients (72%, 13/18) were
male, and 100% of patients were white. Two-thirds of the
patients (12/18) had a diagnosis of Parkinson disease.
At baseline (off treatment), the mean  standard error
of the mean clinical BP readings in the supine position
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Figure 3. Mean hourly ambulatory SBP and DBP (off treatment; open circles) and after 4 weeks of droxidopa (on treatment; closed
circles). Error bars depict SEM. aP-value is for the comparison of the overall change during the period (8 AM–4 PM) for droxidopa
vs. off drug using paired t test. bP-value is for the comparison of the overall change during the period (11 PM–5 AM) for droxidopa
vs. off drug using paired t test. cP-value is for the comparison of the overall change during the period (8 AM–4 PM) for droxidopa
vs. off drug using Wilcoxon signed-rank test. dP-value is for the comparison of the overall change during the period (11 PM–5 AM)
for droxidopa vs. off drug using Wilcoxon signed-rank test. DBP, diastolic blood pressure; SBP, systolic blood pressure; SEM, standard
error of the mean.
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were 130/77  4/2 mm Hg. Mean standing BP readings
were 88/58  4/3 mm Hg, with an average fall of 41/
17  6/3 mm Hg. After baseline assessments and comple-
tion of the randomized clinical trial, patients entered the
open-label extension study and were treated with an indi-
vidually optimized dose of droxidopa (mean  standard de-
viation, 444  129 mg TID; range, 100 mg–600 mg).24-Hour Ambulatory BPAt the end of the washout period, the off-drug mean
24-hour BP was 129/76  3/2 mm Hg (Table 2). After
4 weeks of droxidopa treatment, the mean 24-hour systolic
BP increased by 7.3  2.8 mm Hg (P ¼ .017; 95% CI, 1.5–
13.1 mm Hg; Figure 2A) and mean diastolic BP increased
by 4.8  1.3 mm Hg (P ¼ .002; 95% CI, 2.0–7.7 mm Hg).
The resultant mean 24-hour BP was significantly higher
than off drug (137/81  3/2 mm Hg; P < .017).Daytime BPDuring the off-drug period, the mean daytime (8 AM–4
PM) systolic BP was 123  2 mm Hg (Table 2). Off treat-
ment, 22% of patients (4/18) had individual systolic read-
ings <80 mm Hg and 11% (2/18) had individual readings
<70 mm Hg. As shown in Figures 2B and 3, on-
treatment mean  standard error of the mean daytime sys-
tolic BP readings were significantly increased by
8.4  3.1 mm Hg (P ¼ .014; 95% CI, 1.9–14.9 mm Hg).
On treatment, 11% of patients (2/18) had systolic readings
<80 mm Hg and 1 patient had values <70 mm Hg.Nighttime BPMean systolic BP during the night (11 PM–5 AM) was
significantly higher than during the day at baseline
(136  5 mm Hg vs. 123  2, respectively; P ¼ .02).
Only two patients (both with primary autonomic failure)
Table 3
Categorical changes in systolic and diastolic blood pressure at various hypertensive thresholds in patients (n ¼ 18)
Variable Systolic BP Diastolic BP
160 mm Hg 180 mm Hg 200 mm Hg 100 mm Hg 115 mm Hg
Off
Treatment
On
Treatment
Off
Treatment
On
Treatment
Off
Treatment
On
Treatment
Off
Treatment
On
Treatment
Off
Treatment
On
Treatment
24 hour
Patients with BP
elevations, n (%)
11 (61.1) 14 (77.8) 6 (33.3) 7 (38.9) 2 (11.1) 2 (11.1) 9 (50.0) 11 (61.1) 4 (22.2) 4 (22.2)
Mean  SD elevated
BP readings*
8.2  5.8 10.4  8.5 3.5  3.6 4.6  5.5 1.5  0.7 2.5  2.1 5.9  4.4 8.1  6.7 1.3  0.5 1.3  0.5
Range 1–19 1–33 1–10 1–14 1–2 1–4 1–14 1–20 1–2 1–2
Daytimey
Patients with BP
elevations, n (%)
7 (38.9) 11 (61.1) 4 (22.2) 2 (11.1) 0 0 6 (33.3) 7 (38.9) 2 (11.1) 2 (11.1)
Mean  SD elevated
BP readings*
2.0  0.5 2.6  0.7 1.3  0.5 1.5  0.7 0 0 2.0  1.1 3.3  1.9 1.5  0.7 1.0  0.0
Range 1–2 1–2 1–2 1–2 0 0 1–4 1–6 1–2 1
Nighttimez
Patients with BP
elevations, n (%)
8 (44.4) 10 (55.6) 5 (27.8) 3 (16.7) 0 1 (5.6) 7 (38.9) 8 (44.4) 2 (11.1) 0
Mean  SD elevated
BP readings*
5.9  1.3 6.1  4.0 1.8  1.3 5.7  4.0 0 4.0 3.6  2.9 3.8  2.4 1.0  0.0 0
Range 1–4 1–8 1–4 1–8 0 4 1–8 1–8 1 0
BP, blood pressure; SD, standard deviation.
*Among patients who had BP elevations.
y 8 AM–4 PM.
z 11 PM–5 AM.
824 H. Kaufmann et al. / Journal of the American Society of Hypertension 10(10) (2016) 819–826had a 10% or greater fall in BP at night. The remaining
90% of patients (16/18) had circadian BP abnormalities
with either blunted dipping (a <10% fall in night vs.
day) or reversal of the normal circadian rhythm and higher
values at night (a 10% increase in systolic BP at night vs.
day; 45% [8/18] for each).
In patients receiving droxidopa therapy, mean systolic BPs
were numerically (7.8  4.8 mm Hg) but not significantly
higher at night compared to the off-treatment period
(P ¼ .122; Figures 2C and 3). Similar to the baseline period,
mean systolic BPs were higher at night (143  6 mm Hg)
compared with those during the day (131  3 mm Hg;
P < .017). Seven patients (39%) had a 10-mm Hg increase
in nocturnal systolic BP with treatment with droxidopa
compared with baseline. Four patients (22%) had average
nocturnal systolic BP values>160mmHg; 2 of these patients
(11%) had systolic BP values >180 mm Hg, and no patients
had average systolic BPvalues>200mmHg.Moreover, there
were similar proportions of participants with nighttime sys-
tolic BP readings greater than 160, 180, or 200 mm
Hg at baseline and on treatment (Table 3).
Discussion
This study is the first to examine the effects of droxi-
dopa on ambulatory BP in a group of patients withwell-defined synucleinopathies. Oral administration of
droxidopa significantly increased mean BP during the
day (þ8.4 mm Hg; P ¼ .014), with nonsignificant in-
creases during the night (þ7.8 mm Hg; P ¼ .121). There
have been theoretical concerns that nocturnal BP on drox-
idopa would be higher than those measured during the day
because patients would more likely be supine. However,
only a small subset of patients (2/18, 11%) developed clin-
ically important hypertension at night (mean nocturnal
systolic BP  180 mm Hg) during droxidopa treatment
versus not on treatment. The implications of nocturnal hy-
pertension in patients with autonomic failure are of clin-
ical importance. Elevated nocturnal BP with supine
hypertension is associated with progression of end-organ
target damage and is predictive of cardiovascular events,
including stroke.14,19,21–23 Hence, our findings underscore
the importance of nighttime BP measurements in patients
with nOH because baseline nocturnal BP abnormalities are
common and might be further exacerbated by treatment
with pressor agents. This preliminary study appears to
indicate extreme effects are unlikely in most patients.
When ambulatory BP monitoring is performed, it is essen-
tial to note carefully the timing of pressor agent doses as
well as an accurate timing of sleep. This information is
critical to interpreting the effects of a pressor agent on
the circadian BP profile.
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last daily dose of droxidopa (or any pressor agent) several
hours before retiring for the night, allowing enough time
for the vasoconstrictor effect to diminish. Developing a
higher nocturnal BP on treatment with droxidopa does
not necessarily indicate that the agent should be discontin-
ued or that the risks would be lessened by switching to an
alternative pressor agent. There are no direct comparisons
of droxidopa versus other pressor agents (eg, midodrine),
and it is not known how other pressor agents affect night-
time BP; to the best of our knowledge, ambulatory BP
studies evaluating these effects have not been published.
However, because these agents increase systemic vasocon-
striction, they are all likely to carry the risk of raising
nocturnal BP if taken too close to bedtime. Patients with
nOH should sleep with the head of the bed elevated.24,25
Such a simple maneuver reduces venous return and lowers
BP at night (while supine). Based on the available data with
droxidopa, reduction or elimination of the last dose of the
day may be considered if the patient has supine hyperten-
sion and raising the head of the bed and/or a short-acting
antihypertensives are not adequate for BP control.
Blunted nocturnal dipping is associated with increased
cardiovascular risk.26,27 Patients with nOH have an
increased incidence of blunting of the normal nocturnal
dipping pattern. There are currently no established clinical
care guidelines for the management of high supine BP dur-
ing the night in patients with autonomic failure. Short-
acting antihypertensive agents at night may be useful,28
including calcium antagonists and angiotensin-converting
enzyme inhibitors; however, an agent of choice has not
emerged, and the potential problems of worsening hypoten-
sion when patients get out of bed during the night must be
carefully considered.
An obvious limitation of the study is the small number of
patients. Further studies examining ambulatory BP moni-
toring in a larger cohort are needed to confirm these
findings.
In conclusion, the results of the present study provide ev-
idence that droxidopa, a norepinephrine replacement ther-
apy, leads to increases in ambulatory BP during the day
with an acceptably low risk (estimated to be 10% to
20%) of increasing supine hypertension at night. Ambula-
tory BP monitoring may help to identify the minority of pa-
tients who do develop nocturnal supine hypertension.
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